Bone mass density in lean and overweight women with polycystic ovary syndrome

Abstract

Introduction

Polycystic ovary syndrome is a condition characterized by hormonal and metabolic disturbances that may affect bone health. The purpose of this study was to investigate the effect of polycystic ovary syndrome on bone mineral density and to examine which clinical characteristics of the syndrome could influence bone mineral density.

Materials and methods

We examined 183 premenopausal women: 158 women with polycystic ovary syndrome and 25 healthy age- and body mass index matched controls. Bone mineral density and body composition were investigated by whole-body dual energy X-ray absorption. Total and free testosterone, sex hormone binding globulin, luteinizing hormone, follicle stimulating hormone, estradiol, fasting insulin and glucose, parathyroid hormone, calcium and 25-OH-cholecalciferol were measured. The effect of polycystic ovary syndrome on bone mineral density was analyzed by statistical two-way analysis of variance tests and multiple linear regressions for investigating the connection between bone mineral density and selected clinical parameters.

Results

Women with polycystic ovary syndrome had significantly lower bone density in the lumbar vertebrae L1–L4 compared to healthy controls, independently of body mass index. We found that total lean body mass was the most important associating factor for bone mineral density and these were strongly correlated throughout all regression analyzes. We found no connection between lumbar bone density and androgen status, hyperinsulinemia, estradiol or calcium homeostasis.

Conclusions

Premenopausal women with polycystic ovary syndrome have lower bone mineral density in the lumbar vertebrae L1–L4 compared to healthy controls. Total lean body mass and polycystic ovary syndrome are significantly associated to this finding.

Keywords:

• Polycystic ovary syndrome
• bone density
• pre-menopause
• absorptiometry
• photon
• hormones

Acknowledgments

The authors thank Andreas Voight Dalgaard, cand.act., and Esben Meulengracht Flachs, cand.scient., PhD, for assisting with statistical advisory and analyses.

CRediT author statement

N. F. M.: formal analysis, investigation, writing – original draft, visualization. M. A.: Resources, data curation, writing – review and editing, supervision. P. F. S.: Conceptualization, methodology, resources, data curation, writing – review and editing, supervision, project administration.

Disclosure statement

All authors have no conflicts of interest.

Additional information

Funding

The Hvidovre trial received financial support from the Danish Hospital Foundation for Medical Research, Region of Copenhagen, The Faroe Islands and Greenland, Svend Aage Bang’s Foundation and Diabetesforeningen. The Herlev trial was supported by the Research Fund of Region Zealand, the local Research Committee, Herlev University Hospital, the Department of Gynecology and Obstetrics, Herlev University Hospital, Merck Serono, Snedkermester Sophus Jacobsen and wife Astrid Jacobsen's Foundation.